Get the Stockscreener App
11.54
0.69%
-0.08
After Hours:
11.80
0.26
+2.25%
Absci Corp stock is traded at $11.54, with a volume of 5.47M.
It is down -0.69% in the last 24 hours and up +80.31% over the past month.
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
See More
Previous Close:
$11.62
Open:
$11.63
24h Volume:
5.47M
Relative Volume:
0.95
Market Cap:
$1.95B
Revenue:
$2.80M
Net Income/Loss:
$-115.18M
P/E Ratio:
-13.62
EPS:
-0.8473
Net Cash Flow:
$-94.03M
1W Performance:
+1.67%
1M Performance:
+80.31%
6M Performance:
+195.90%
1Y Performance:
+316.61%
1-Day Range:
$11.33
$12.00
1-Week Range:
$10.82
$12.00
52-Week Range:
$2.24
$12.05
Absci Corp Stock (ABSI) Company Profile
Name
Absci Corp
Sector
Industry
Phone
(360) 949-1041
Address
18105 SE MILL PLAIN BLVD, VANCOUVER
Compare ABSI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
11.54 | 1.96B | 2.80M | -115.18M | -94.03M | -0.8473 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-02-25 | Initiated | JP Morgan | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jan-22-25 | Initiated | Needham | Buy |
| Oct-02-24 | Initiated | Guggenheim | Buy |
| Jul-03-24 | Initiated | Morgan Stanley | Overweight |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-04-23 | Initiated | H.C. Wainwright | Buy |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Jul-18-22 | Initiated | Truist | Buy |
| Mar-02-22 | Resumed | Cowen | Market Perform |
| Feb-01-22 | Initiated | Berenberg | Buy |
| Nov-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Aug-16-21 | Initiated | BofA Securities | Neutral |
| Aug-16-21 | Initiated | Cowen | Market Perform |
| Aug-16-21 | Initiated | Credit Suisse | Outperform |
| Aug-16-21 | Initiated | Stifel | Hold |
View All
Absci Corp Stock (ABSI) Latest News
Absci Stock (ABSI) Opinions on Positive Phase 1 Data for ABS-201 - Moomoo
ABSCI CORP (ABSI) soars 36.0%: Is further upside left in the stock? - MSN
A Quick Look at Today's Ratings for Absci Corp(ABSI.US), With a Forecast Between $11 to $16 - Moomoo
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program - Yahoo Finance
Absci (NASDAQ:ABSI) Rating Increased to Hold at Wall Street Zen - MarketBeat
Form 4 Absci Corp For: 26 June By Investing.com - Investing.com Australia
Absci (NASDAQ: ABSI) CEO has 59,896 shares withheld for RSU tax obligation - Stock Titan
Absci (ABSI) Is Up 37.8% After ABS-201 Data And Equity RaiseHas The Bull Case Changed? - Yahoo Finance
Absci Corporation (NASDAQ:ABSI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Absci Corp Company Profile & Introduction - Moomoo
H.C. Wainwright raises Absci stock price target on trial data By Investing.com - Investing.com South Africa
Guggenheim Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $15 - Moomoo
H.C. Wainwright raises Absci stock price target on trial data - Investing.com UK
Morgan Stanley Maintains Absci Corp(ABSI.US) With Hold Rating, Raises Target Price to $10.08 - Moomoo
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss Study - Yahoo Finance
ABSI Forecast — Price Target — Prediction for 2027 - TradingView
Absci Corporation Stock 12‑Month Price Target Raised to $12, Implies 19% Upside - TradingView
ABSI Maintained by HC Wainwright & Co. -- Price Target Raised to $16.00 - GuruFocus
Absci Corporation Stock 12‑Month Price Target Raised to $11.2, Implies 11% Upside - TradingView
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Tracking Cathie Wood: Major AI Biotech Discovery Bet on Recursion, Heavy Reduction in Absci Holdings - Moomoo
Cathie Wood's investment moves on June 24! Significant increase in holdings of Recursion, an AI-driven drug discovery company; sold over 670,000 shares of Absci - Moomoo
United StatesGoodwin Guides Absci On Pricing Of $100 Million Underwritten Offering - Mondaq
Why Did UAL, GLW, ABSI Stocks Surge To 52-Week Highs Today? - TradingView
Absci (ABSI) Is Up 40.3% After Positive ABS-201 Data And Equity Raise Has The Bull Case Changed? - simplywall.st
Biopharma bites: Remix's reverse merger, Absci's raise, ADC's layoffs, and a new R&D head for Lundbeck - FirstWord Pharma
ABSI stock eyes best day ever after positive hair loss drug data, $100M Lilly-backed raise - MSN
ABSI Reiterated by Needham -- Price Target Raised to $11.00 - GuruFocus
Form 424B5 Absci Corp For: 24 June By Investing.com - Investing.com Nigeria
Absci Announces $100 Million Public Equity Offering - TipRanks
Absci (NASDAQ: ABSI) sells 13.5M shares at $7.41; Eli Lilly buys 5.4M - Stock Titan
Absci (NASDAQ: ABSI) prices $100M underwritten equity deal to fund ABS-201 - Stock Titan
Absci rises on Phase 1 ABS-201 update and $100 million raise - TechStock²
Eli Lilly dives into hair loss treatments with investment in AI startup Absci - statnews.com
ABSI Stock Eyes Best Day Ever After Positive Hair Loss Drug Data, $100M Lilly-Backed Raise - Yahoo Finance
Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain (NASDAQ:ABSI) - Seeking Alpha
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $13 - Moomoo
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Exclusive BAC Article: Absci Corporation; Positive Phase 1 Data ABS-201 AGA, Interim And Final POC Data 2nd Half 2026/Early 2027, Respectively, Advancement Endometriosis And Catalysts (NASDAQ:ABSI) - Seeking Alpha
Absci's ABS-201 Phase 1 Data De-Risks Hair Loss Program Ahead of Efficacy Readout, Truist Says - Moomoo
Absci (ABSI) Surges 20% in Premarket Following $100M Financing D - GuruFocus
ABSI Maintains by BTIG -- Price Target Raised to $13 - GuruFocus
Portland-area biotech receives $100M investment led by Eli Lilly - The Business Journals
Absci reports positive Phase 1 data for ABS-201 - grafa.com
Absci reports phase 1 interim data for hair loss drug ABS-201 - Investing.com South Africa
Absci (ABSI) Stock Pops As Wall Street Hikes Price Targets - StocksToTrade
Absci shares soar after positive early clinical results for hair loss therapy (ABSI) - MSN
Absci surges on Eli Lilly, private equity investments - MSN
Absci (ABSI) Stock Rallies As Wall Street Boosts Targets - timothysykes.com
Absci Shares Soar After Positive Early Clinical Results for Hair Loss Therapy (ABSI) - Yahoo Finance
Why is Absci stock surging today? By Investing.com - Investing.com Nigeria
Absci Corp Stock (ABSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Absci Corp Stock (ABSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Busch Andreas | Chief Innovation Officer |
Mar 12 '26 |
Buy |
2.29 |
100,000 |
229,000 |
421,446 |
| Pangalos Menelas N | Director |
Feb 27 '26 |
Buy |
2.74 |
75,095 |
205,760 |
189,055 |
| McClain Sean | Chief Executive Officer |
Feb 23 '26 |
Option Exercise |
1.21 |
396,399 |
479,643 |
8,730,966 |
| McClain Sean | Chief Executive Officer |
Feb 02 '26 |
Sale |
2.99 |
26,761 |
80,015 |
8,334,567 |
| Jonasson Zachariah | CFO / CBO |
Feb 02 '26 |
Sale |
2.99 |
17,496 |
52,313 |
383,538 |
| VAN HOUTEN FRANS | Director |
Dec 05 '25 |
Buy |
3.72 |
40,000 |
148,800 |
63,320 |
| Pangalos Menelas N | Director |
Sep 22 '25 |
Buy |
2.66 |
95,785 |
254,788 |
113,960 |
| Bedrick Todd | SVP, CAO |
Sep 22 '25 |
Buy |
2.70 |
10,000 |
27,000 |
180,428 |
| Busch Andreas | Chief Innovation Officer |
Jul 28 '25 |
Buy |
3.04 |
50,000 |
152,000 |
327,264 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):